ATRA 24.00 Atara Biotherapeutics Inc. $ATRA Hit a
Post# of 47155
Posted On: 11/13/2014 10:29:19 AM
ATRA 24.00 Atara Biotherapeutics Inc. $ATRA Hit a 52 week high of 24.00 Closing the day 09:41 at 24.00 +1.45 +6.43% With a day low of 22.75 and a total volume of 11,251.
ATRA Recent Posts: http://investorshangout.com/Atara-Biotherapeu...TRA-90614/
ATRA Atara Biotherapeutics Inc. Recent Headline News
Market Maker Surveillance Report. ROIAK, GHDX, ATRA, ASPS, XONE, XENE, Losing Stocks With Lowest Price Friction For Wednesday, November 12th 2014
M2 - Thu Nov 13, 2:40AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4945 companies with "abnormal" market making, 2475 companies with positive Friction Factors and 2275 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Radio One Inc (NASDAQ:ROIAK), GENOMIC HEALTH, INC. (NASDAQ:GHDX), ATRATECH INC (NASDAQ:ATRA), ALTISOURCE PORTFOLIO SOLUTIONS SA (NASDAQ:ASPS), (NASDAQ:XONE), (NASDAQ:XENE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ASPS: 58.85 (-1.65), ROIAK: 1.99 (+0.12), XENE: 12.74 (-0.67), XONE: 19.72 (-0.32), ATRA: 23.64 (+1.09), GHDX: 33.08 (+0.09)
Atara Biotherapeutics net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 10:44AM CST
ATRA: 23.64 (+1.09)
Atara Biotherapeutics reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:29AM CST
ATRA: 23.64 (+1.09)
Atara Biotherapeutics Announces Third Quarter 2014 Operating Results
GlobeNewswire - Wed Nov 12, 5:00AM CST
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today reported financial results for the third quarter and nine months ended September 30, 2014.
ATRA: 23.64 (+1.09)
Baupost Takes Big Stakes In Forward Pharma, PBF Energy, Atara Biotherapeutics
ValueWalk - at Seeking Alpha - Tue Nov 11, 11:53AM CST
Even though Forward Pharma only has a single drug in the pipeline and none on the market, it doesn't present the same kinds of risks as your typical pharma IPO. In most cases, pharmaceutical companies without any drugs on the market are the very...
FWP: 22.95 (+0.45), PBF: 26.83 (-0.33), ATRA: 23.64 (+1.09)
Atara Biotherapeutics: Ripe To Buy Leading Up To Quiet Period Expiration
Don Dion - at Seeking Alpha - Sat Nov 08, 8:37AM CST
ATRA: 23.64 (+1.09)
Atara Biotherapeutics' Collaborating Investigators to Present Data at the American Society of Hematology Annual Meeting 2014
GlobeNewswire - Thu Nov 06, 8:45AM CST
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present at the Annual Meeting of the American Society of Hematology (ASH) 2014. Data will be presented regarding ongoing clinical studies with cytomegalovirus (CMV) T cell therapy. The meeting will be held in San Francisco December 6-9th, 2014.
ATRA: 23.64 (+1.09)
U.S. IPO Weekly Recap: Boots, Barrels And Busts
Renaissance Capital IPO Research - Seeking Alpha - Sun Nov 02, 4:14AM CST
Four IPOs raised $1.2 billion during the past week, the third week in a row with five or less. Year-to-date, the IPO market has seen 235 initial public offerings raise $75 billion. The week's energy, health care, finance and consumer IPOs saw...
MOLG: 8.66 (+0.26), SHLX: 36.53 (-0.25), DPLO: 21.91 (-0.11), BOOT: 19.18 (+0.32), FSAM: 14.00 (-0.09), ATRA: 23.64 (+1.09), SIEN: 17.43 (-0.07)
InsiderInsights.com Daily Round Up 10/23/14: AAMC, YELP, ENTG, AIRT
InsiderInsights - at Seeking Alpha - Fri Oct 24, 9:29AM CDT
NICK: 12.68 (-0.28), CPSS: 7.17 (-0.01), ENTG: 13.60 (+0.05), POOL: 60.16 (-0.20), AGCO: 44.60 (-0.25), AAMC: 530.00 (+4.00), AIRT: 15.15 (-0.39), ATRA: 23.64 (+1.09), LIVE: 3.62 (+0.10), SHLD: 38.76 (+1.00), K: 63.80 (+0.12), OPK: 8.47 (+0.10), MYCC: 19.40 (+0.03), CUDA: 34.81 (+0.31), OHI: 37.92 (+0.13), COST: 137.39 (+0.49), NMBL: 28.20 (+0.11), YELP: 60.83 (+0.25), SYK: 88.86 (+0.28)
InsiderInsights.com Daily Round Up 10/21/14: AGCO, ESPR, FMI, BKCC
InsiderInsights - at Seeking Alpha - Wed Oct 22, 9:56AM CDT
LDRH: 35.97 (-0.04), BKCC: 8.97 (+0.02), RDEN: 18.82 (+0.31), AGCO: 44.60 (-0.25), MLNK: 3.52 (+0.06), ATRA: 23.64 (+1.09), DHR: 82.52 (+0.16), SHLD: 38.76 (+1.00), GOOG: 548.16 (+0.85), HPQ: 36.61 (+0.10), ATNI: 72.97 (-0.19), PM: 88.17 (+0.27), ESPR: 30.89 (+1.22), FMI: 25.26 (+0.16), LNKD: 234.17 (+3.04), MAT: 31.19 (-0.12), SYK: 88.86 (+0.28), IPGP: 72.93 (+0.02)
Atara Biotherapeutics Doses First Patient in Phase 1 Clinical Study of STM 434, an Activin Inhibitor
GlobeNewswire - Wed Oct 22, 5:50AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced dosing of the first patient in its Phase 1 clinical study of STM 434, an Activin inhibitor, in patients with ovarian cancer and other solid tumors. The study is designed to assess the safety, tolerability and efficacy of STM 434 as a single therapy and in combination with liposomal doxorubicin. Further information regarding the clinical study can be found at http://www.clinicaltrials.gov/ct2/show/NCT02262455.
ATRA: 23.64 (+1.09)
U.S. IPO Weekly Recap: 5 IPOs Achieve Moderate Gains During The Market Slide And A Biotech Rejection
Renaissance Capital IPO Research - at Seeking Alpha - Sun Oct 19, 12:54PM CDT
Five initial public offerings collectively raised $1.3 billion during the past week, bringing the year's total to 228 IPOs and $73.5 billion raised, a 35% increase over this time last year by deal count and an 84% increase by proceeds. The S&P...
DM: 34.83 (+0.53), FWP: 22.95 (+0.45), ATRA: 23.64 (+1.09), ZAYO: 23.52 (+0.26), GWB: 21.20 (+0.40)
Photo Release -- Nasdaq Welcomes Atara Biotherapeutics, Inc. (Nasdaq: ATRA) to The Nasdaq Stock Market
GlobeNewswire - Thu Oct 16, 9:45AM CDT
Nasdaq (Nasdaq:NDAQ) announced that trading of Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company, commenced on The Nasdaq Stock Market on October 16, 2014.
ATRA: 23.64 (+1.09), NDAQ: 44.02 (-0.01)
Atara Biotherapeutics (Nasdaq: ATRA) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
GlobeNewswire - Thu Oct 16, 5:41AM CDT
--
ATRA: 23.64 (+1.09), NDAQ: 44.02 (-0.01)
IPO Preview: Atara Biotherapeutics
IPOdesktop - Seeking Alpha - Thu Oct 16, 12:56AM CDT
Based in Brisbane, CA, Atara Biotherapeutics (Pending: ATRA ) scheduled a $75 million IPO on the Nasdaq with a market capitalization of $291 million at a price range midpoint of $15 for Thursday, Oct. 16, 2014. The full IPO calendar is available...
ATRA: 23.64 (+1.09)
Atara Biotherapeutics Announces Pricing of Its Initial Public Offering
GlobeNewswire - Wed Oct 15, 10:10PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $11.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Select Market under the ticker symbol "ATRA" on October 16, 2014. In addition, Atara has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from Atara at the initial public offering price to cover over-allotments, if any. The offering is expected to close on October 21, 2014, subject to customary closing conditions.
ATRA: 23.64 (+1.09)
IPO Stock Watch: Biotech Forward Pharma Falls On IPO
at Investor's Business Daily - Wed Oct 15, 3:06PM CDT
Forward Pharma, the largest biotech IPO this year, tanked on its first day of trading. Denmark-based Forward Pharma (FWP) raised $221 million by pricing 10.5 million shares at 21, the midpoint of its 20-22 range. The stock was trading near 17.50,...
DM: 34.83 (+0.53), BIIB: 321.21 (+0.19), KITE: 43.27 (+1.60), FWP: 22.95 (+0.45), XENE: 12.74 (-0.67), ATRA: 23.64 (+1.09), VBAY: (), GWB: 21.20 (+0.40)
Biotechs lead list of 7 IPOs
at Investor's Business Daily - Mon Oct 13, 5:46PM CDT
Four more biotech IPOs are scheduled to debut this week. Forward Pharma (FWP) looks to raise $200 mil by offering 9.5 mil shares at a price range of 20-22. Atara Biotherapeutics (ATRA) plans to raise $75 mil by selling 5 mil shares at 14-16. Xenon...
FWP: 22.95 (+0.45), XENE: 12.74 (-0.67), ATRA: 23.64 (+1.09), VBAY: ()
IPO Calendar: Biotech Companies Lead List Of 7 IPOs
at Investor's Business Daily - Mon Oct 13, 3:33PM CDT
In a big year for biotech IPOs, four more are scheduled to debut this week, including the year's largest -- Forward Pharma. Seven initial public offerings in total are expected this week, looking to raise a combined $1.7 billion. Forward Pharma (FWP)...
DM: 34.83 (+0.53), BIIB: 321.21 (+0.19), FWP: 22.95 (+0.45), KITE: 43.27 (+1.60), XENE: 12.74 (-0.67), MRK: 59.79 (+0.48), CFG: 23.77 (-0.09), ZAYO: 23.52 (+0.26), ATRA: 23.64 (+1.09), TEVA: 58.21 (-0.23), VBAY: (), GWB: 21.20 (+0.40)
Atara Biotherapeutics Announces Immunotherapy Alliance With Memorial Sloan Kettering Cancer Center
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Atara Biotherapeutics (Atara) today announced that they have entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development and commercialization of allogeneic T-cell therapies for the treatment of certain cancers and persistent viral infections. Under the terms of the agreement, Atara will have the option to acquire a worldwide license to three clinical stage T-cell therapies consisting of:
ATRA: 23.64 (+1.09)
ATRA Recent Posts: http://investorshangout.com/Atara-Biotherapeu...TRA-90614/
ATRA Atara Biotherapeutics Inc. Recent Headline News
Market Maker Surveillance Report. ROIAK, GHDX, ATRA, ASPS, XONE, XENE, Losing Stocks With Lowest Price Friction For Wednesday, November 12th 2014
M2 - Thu Nov 13, 2:40AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4945 companies with "abnormal" market making, 2475 companies with positive Friction Factors and 2275 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Radio One Inc (NASDAQ:ROIAK), GENOMIC HEALTH, INC. (NASDAQ:GHDX), ATRATECH INC (NASDAQ:ATRA), ALTISOURCE PORTFOLIO SOLUTIONS SA (NASDAQ:ASPS), (NASDAQ:XONE), (NASDAQ:XENE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ASPS: 58.85 (-1.65), ROIAK: 1.99 (+0.12), XENE: 12.74 (-0.67), XONE: 19.72 (-0.32), ATRA: 23.64 (+1.09), GHDX: 33.08 (+0.09)
Atara Biotherapeutics net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 10:44AM CST
ATRA: 23.64 (+1.09)
Atara Biotherapeutics reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:29AM CST
ATRA: 23.64 (+1.09)
Atara Biotherapeutics Announces Third Quarter 2014 Operating Results
GlobeNewswire - Wed Nov 12, 5:00AM CST
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today reported financial results for the third quarter and nine months ended September 30, 2014.
ATRA: 23.64 (+1.09)
Baupost Takes Big Stakes In Forward Pharma, PBF Energy, Atara Biotherapeutics
ValueWalk - at Seeking Alpha - Tue Nov 11, 11:53AM CST
Even though Forward Pharma only has a single drug in the pipeline and none on the market, it doesn't present the same kinds of risks as your typical pharma IPO. In most cases, pharmaceutical companies without any drugs on the market are the very...
FWP: 22.95 (+0.45), PBF: 26.83 (-0.33), ATRA: 23.64 (+1.09)
Atara Biotherapeutics: Ripe To Buy Leading Up To Quiet Period Expiration
Don Dion - at Seeking Alpha - Sat Nov 08, 8:37AM CST
ATRA: 23.64 (+1.09)
Atara Biotherapeutics' Collaborating Investigators to Present Data at the American Society of Hematology Annual Meeting 2014
GlobeNewswire - Thu Nov 06, 8:45AM CST
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present at the Annual Meeting of the American Society of Hematology (ASH) 2014. Data will be presented regarding ongoing clinical studies with cytomegalovirus (CMV) T cell therapy. The meeting will be held in San Francisco December 6-9th, 2014.
ATRA: 23.64 (+1.09)
U.S. IPO Weekly Recap: Boots, Barrels And Busts
Renaissance Capital IPO Research - Seeking Alpha - Sun Nov 02, 4:14AM CST
Four IPOs raised $1.2 billion during the past week, the third week in a row with five or less. Year-to-date, the IPO market has seen 235 initial public offerings raise $75 billion. The week's energy, health care, finance and consumer IPOs saw...
MOLG: 8.66 (+0.26), SHLX: 36.53 (-0.25), DPLO: 21.91 (-0.11), BOOT: 19.18 (+0.32), FSAM: 14.00 (-0.09), ATRA: 23.64 (+1.09), SIEN: 17.43 (-0.07)
InsiderInsights.com Daily Round Up 10/23/14: AAMC, YELP, ENTG, AIRT
InsiderInsights - at Seeking Alpha - Fri Oct 24, 9:29AM CDT
NICK: 12.68 (-0.28), CPSS: 7.17 (-0.01), ENTG: 13.60 (+0.05), POOL: 60.16 (-0.20), AGCO: 44.60 (-0.25), AAMC: 530.00 (+4.00), AIRT: 15.15 (-0.39), ATRA: 23.64 (+1.09), LIVE: 3.62 (+0.10), SHLD: 38.76 (+1.00), K: 63.80 (+0.12), OPK: 8.47 (+0.10), MYCC: 19.40 (+0.03), CUDA: 34.81 (+0.31), OHI: 37.92 (+0.13), COST: 137.39 (+0.49), NMBL: 28.20 (+0.11), YELP: 60.83 (+0.25), SYK: 88.86 (+0.28)
InsiderInsights.com Daily Round Up 10/21/14: AGCO, ESPR, FMI, BKCC
InsiderInsights - at Seeking Alpha - Wed Oct 22, 9:56AM CDT
LDRH: 35.97 (-0.04), BKCC: 8.97 (+0.02), RDEN: 18.82 (+0.31), AGCO: 44.60 (-0.25), MLNK: 3.52 (+0.06), ATRA: 23.64 (+1.09), DHR: 82.52 (+0.16), SHLD: 38.76 (+1.00), GOOG: 548.16 (+0.85), HPQ: 36.61 (+0.10), ATNI: 72.97 (-0.19), PM: 88.17 (+0.27), ESPR: 30.89 (+1.22), FMI: 25.26 (+0.16), LNKD: 234.17 (+3.04), MAT: 31.19 (-0.12), SYK: 88.86 (+0.28), IPGP: 72.93 (+0.02)
Atara Biotherapeutics Doses First Patient in Phase 1 Clinical Study of STM 434, an Activin Inhibitor
GlobeNewswire - Wed Oct 22, 5:50AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced dosing of the first patient in its Phase 1 clinical study of STM 434, an Activin inhibitor, in patients with ovarian cancer and other solid tumors. The study is designed to assess the safety, tolerability and efficacy of STM 434 as a single therapy and in combination with liposomal doxorubicin. Further information regarding the clinical study can be found at http://www.clinicaltrials.gov/ct2/show/NCT02262455.
ATRA: 23.64 (+1.09)
U.S. IPO Weekly Recap: 5 IPOs Achieve Moderate Gains During The Market Slide And A Biotech Rejection
Renaissance Capital IPO Research - at Seeking Alpha - Sun Oct 19, 12:54PM CDT
Five initial public offerings collectively raised $1.3 billion during the past week, bringing the year's total to 228 IPOs and $73.5 billion raised, a 35% increase over this time last year by deal count and an 84% increase by proceeds. The S&P...
DM: 34.83 (+0.53), FWP: 22.95 (+0.45), ATRA: 23.64 (+1.09), ZAYO: 23.52 (+0.26), GWB: 21.20 (+0.40)
Photo Release -- Nasdaq Welcomes Atara Biotherapeutics, Inc. (Nasdaq: ATRA) to The Nasdaq Stock Market
GlobeNewswire - Thu Oct 16, 9:45AM CDT
Nasdaq (Nasdaq:NDAQ) announced that trading of Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company, commenced on The Nasdaq Stock Market on October 16, 2014.
ATRA: 23.64 (+1.09), NDAQ: 44.02 (-0.01)
Atara Biotherapeutics (Nasdaq: ATRA) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
GlobeNewswire - Thu Oct 16, 5:41AM CDT
--
ATRA: 23.64 (+1.09), NDAQ: 44.02 (-0.01)
IPO Preview: Atara Biotherapeutics
IPOdesktop - Seeking Alpha - Thu Oct 16, 12:56AM CDT
Based in Brisbane, CA, Atara Biotherapeutics (Pending: ATRA ) scheduled a $75 million IPO on the Nasdaq with a market capitalization of $291 million at a price range midpoint of $15 for Thursday, Oct. 16, 2014. The full IPO calendar is available...
ATRA: 23.64 (+1.09)
Atara Biotherapeutics Announces Pricing of Its Initial Public Offering
GlobeNewswire - Wed Oct 15, 10:10PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $11.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Select Market under the ticker symbol "ATRA" on October 16, 2014. In addition, Atara has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from Atara at the initial public offering price to cover over-allotments, if any. The offering is expected to close on October 21, 2014, subject to customary closing conditions.
ATRA: 23.64 (+1.09)
IPO Stock Watch: Biotech Forward Pharma Falls On IPO
at Investor's Business Daily - Wed Oct 15, 3:06PM CDT
Forward Pharma, the largest biotech IPO this year, tanked on its first day of trading. Denmark-based Forward Pharma (FWP) raised $221 million by pricing 10.5 million shares at 21, the midpoint of its 20-22 range. The stock was trading near 17.50,...
DM: 34.83 (+0.53), BIIB: 321.21 (+0.19), KITE: 43.27 (+1.60), FWP: 22.95 (+0.45), XENE: 12.74 (-0.67), ATRA: 23.64 (+1.09), VBAY: (), GWB: 21.20 (+0.40)
Biotechs lead list of 7 IPOs
at Investor's Business Daily - Mon Oct 13, 5:46PM CDT
Four more biotech IPOs are scheduled to debut this week. Forward Pharma (FWP) looks to raise $200 mil by offering 9.5 mil shares at a price range of 20-22. Atara Biotherapeutics (ATRA) plans to raise $75 mil by selling 5 mil shares at 14-16. Xenon...
FWP: 22.95 (+0.45), XENE: 12.74 (-0.67), ATRA: 23.64 (+1.09), VBAY: ()
IPO Calendar: Biotech Companies Lead List Of 7 IPOs
at Investor's Business Daily - Mon Oct 13, 3:33PM CDT
In a big year for biotech IPOs, four more are scheduled to debut this week, including the year's largest -- Forward Pharma. Seven initial public offerings in total are expected this week, looking to raise a combined $1.7 billion. Forward Pharma (FWP)...
DM: 34.83 (+0.53), BIIB: 321.21 (+0.19), FWP: 22.95 (+0.45), KITE: 43.27 (+1.60), XENE: 12.74 (-0.67), MRK: 59.79 (+0.48), CFG: 23.77 (-0.09), ZAYO: 23.52 (+0.26), ATRA: 23.64 (+1.09), TEVA: 58.21 (-0.23), VBAY: (), GWB: 21.20 (+0.40)
Atara Biotherapeutics Announces Immunotherapy Alliance With Memorial Sloan Kettering Cancer Center
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Atara Biotherapeutics (Atara) today announced that they have entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development and commercialization of allogeneic T-cell therapies for the treatment of certain cancers and persistent viral infections. Under the terms of the agreement, Atara will have the option to acquire a worldwide license to three clinical stage T-cell therapies consisting of:
ATRA: 23.64 (+1.09)
(0)
(0)